A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Exclusion Criteria

• •1. Have present or progressive accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to study drug administration. The participant can receive diuretic drugs as needed per the treating physician. Consult with the sponsor if the participant has more than trivial/trace fluid accumulation.
• •2. Prior treatment with E7386 or prior therapy with anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (example, CTLA-4, OX 40, CD137) that was discontinued due to a Grade 3 or higher immune-related (ir)AE
• •4. Any active infection requiring systemic treatment
• •5. Have severe hypersensitivity to study drugs and/or any of its excipients
• •6. Have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
• •7. Have an active autoimmune disease that has required systemic treatment in the past 2 years
• •8. Have a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
• •9. Any bone disease/conditions as follows:
• •* Osteoporosis with T-score \<-2.5 by DXA scan
• •* Metabolic bone disease, such as hyperparathyroidism, Paget's disease or osteomalacia
• •* Symptomatic hypercalcemia requiring bisphosphonate therapy
• •* History of any fracture within 6 months prior to starting study drug
• •* History of symptomatic vertebral fragility fracture or any fragility fracture
• •* Moderate or severe morphometric vertebral fracture at baseline.
• •* Any condition requiring orthopedic intervention.
• •* Bone metastases not being treated with a bisphosphonate or denosumab
• •10. Active viral hepatitis (B or C) as demonstrated by positive serology for participants with melanoma and CRC. Dual active hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection at study entry for participants with HCC
• •11. Known to be human immunodeficiency virus (HIV) positive
• •12. Received blood/platelet transfusion or G-CSF within 4 weeks before study entry
• •13. For Melanoma only, participants with ocular melanoma are excluded. Note: Participants with mucosal melanoma will not exceed 20% of the enrolled participants in melanoma cohort in Phase 2.
• •14. For CRC only, participants are excluded if:
• •\- have a tumor that is microsatellite instability high (MSI H)/ DNA mismatch repair-deficient (dMMR) positive
• •15. For HCC only, participants are excluded if:
• •* Clear invasion to bile duct
• •* Have had esophageal or gastric variceal bleeding within the last 6 months. Participants in triplet treatment cohorts will be screened for esophageal or gastric varices unless such screening has been performed in the past 3 months before first dose of treatment. If varices are present, they should be treated according to institutional standards before starting study intervention; esophageal or gastric varices that require interventional treatment within 28 days prior to first dose of study drug are excluded
• •* History of hepatic encephalopathy within 6 months prior to starting study drug unresponsive to therapy within 3 days. Participants on rifaximin or lactulose during screening to control their hepatic encephalopathy are not allowed
• •16. For participants in the triplet treatment cohorts only:
• •* Proteinuria greater than (\>) 1+ on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Participants with urine protein \>=1 gram per 24 hours (g/24 hours) will be ineligible
• •* Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic INR monitoring (example, warfarin or similar agents). Treatment with low molecular weight heparin and factor X inhibitors is permitted
• •* Clinically significant hemoptysis from any source or tumor bleeding within 3 weeks prior to the first dose of study drug
• •* Pre-existing \>=Grade 3 gastrointestinal or non-gastrointestinal fistula